Grifols/$GRFS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Grifols
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Ticker
$GRFS
Sector
Primary listing
Employees
23,833
Headquarters
Website
Grifols Metrics
BasicAdvanced
$7.5B
16.61
$0.52
0.98
$0.14
1.65%
Price and volume
Market cap
$7.5B
Beta
0.98
52-week high
$11.14
52-week low
$6.19
Average daily volume
649K
Dividend rate
$0.14
Financial strength
Current ratio
2.636
Quick ratio
0.926
Long term debt to equity
119.998
Total debt to equity
126.869
Dividend payout ratio (TTM)
0.32%
Interest coverage (TTM)
2.73%
Profitability
EBITDA (TTM)
1,901.253
Gross margin (TTM)
40.09%
Net profit margin (TTM)
3.99%
Operating margin (TTM)
18.89%
Effective tax rate (TTM)
37.62%
Revenue per employee (TTM)
$356,660
Management effectiveness
Return on assets (TTM)
4.18%
Return on equity (TTM)
4.99%
Valuation
Price to earnings (TTM)
16.606
Price to revenue (TTM)
0.662
Price to book
1.26
Price to tangible book (TTM)
-1.47
Price to free cash flow (TTM)
7.084
Free cash flow yield (TTM)
14.12%
Free cash flow per share (TTM)
1.218
Dividend yield (TTM)
1.65%
Growth
Revenue change (TTM)
9.32%
Earnings per share change (TTM)
132.60%
3-year revenue growth (CAGR)
12.66%
10-year revenue growth (CAGR)
7.40%
3-year earnings per share growth (CAGR)
67.45%
10-year earnings per share growth (CAGR)
-4.84%
10-year dividend per share growth (CAGR)
-7.44%
What the Analysts think about Grifols
Analyst ratings (Buy, Hold, Sell) for Grifols stock.
Bulls say / Bears say
Strong Q1 profitability jump: Grifols reported net profit of €60m in Q1 2025, a 179% year-on-year increase, with adjusted EBITDA up 14.2% to €400m and net revenue rising 7.4%, driven by its plasma-derived medicine business (Reuters).
AI-powered R&D enhances growth prospects: Following its acquisition of Alkahest, Grifols uses AI to analyze over 6 million plasma samples to develop therapies for Alzheimer’s and Parkinson’s, potentially opening lucrative neurodegenerative disease markets (Financial Times).
Debt reduction bolsters financial flexibility: In Q1 2025, Grifols reduced its net debt to €8.149bn and lowered leverage to 4.5x EBITDA from 6.8x a year earlier, improving its balance sheet strength (Cinco Días).
Persistent negative free cash flow: Although improved by €209m, Grifols’s free cash flow pre-M&A remained negative €44m in Q1 2025, indicating ongoing cash burn challenges (Cinco Días).
Regulatory and governance risk: Spain’s CNMV fined Grifols and its directors €1.4m for financial reporting errors between 2021 and 2023, with appeals ongoing, highlighting corporate oversight concerns (Financial Times).
Exposure to China regulatory headwinds: Grifols experienced a 9.4% drop in albumin sales in Q1 due to a planned license renewal in China, underscoring vulnerability to external regulatory disruptions (Cinco Días).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Grifols Financial Performance
Revenues and expenses
Grifols Earnings Performance
Company profitability
Grifols News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Grifols stock?
Grifols (GRFS) has a market cap of $7.5B as of November 06, 2025.
What is the P/E ratio for Grifols stock?
The price to earnings (P/E) ratio for Grifols (GRFS) stock is 16.61 as of November 06, 2025.
Does Grifols stock pay dividends?
Yes, the Grifols (GRFS) stock pays dividends to shareholders. As of November 06, 2025, the dividend rate is $0.14238 and the yield is 1.65%. Grifols has a payout ratio of 0.32% on a trailing twelve-month basis.
When is the next Grifols dividend payment date?
The next Grifols (GRFS) dividend payment date is unconfirmed.
What is the beta indicator for Grifols?
Grifols (GRFS) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.